Related Experiment Videos
Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer
P. Sevelda1, N. Vavra, R. Fitz
1Oncologic Unit of the 1st Department of Gynecology & Obstetrics, University of Vienna and Department of Chemotherapy, University of Vienna, Austria.
Abstract:
Between October 1988 and March 1991, 23 ovarian cancer patients with progressive disease whilst receiving second- or third-line polychemotherapy received subcutaneously 3.6 mg Goserelin, a GnRH analogue, at monthly intervals until further tumor progression. Four patients (17.4%) achieved partial response, 7 patients (30.4%) had stable disease and 12 patients (52.2%) showed further tumor progression. Median time to tumor progression was 8.5, 5.3 and 2.1 months, respectively (Mantel test, P = 0.0003). Ten out of 11 patients who showed partial response or no change had grade 2 or grade 3 tumors. We conclude that Goserelin shows evidence of antitumor activity also in grade 2 and grade 3 ovarian carcinoma. It offers a therapeutic alternative to a group of patients, in whom we usually terminate cytotoxic treatment.
Insights
Goserelin, a GnRH analogue, demonstrated antitumor activity in patients with advanced ovarian cancer, offering a new treatment option. This study found Goserelin effective in managing progressive disease, particularly in higher-grade tumors.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ovarian carcinoma often progresses despite conventional polychemotherapy.
- There is a need for alternative treatments for patients with progressive ovarian cancer.
Purpose of the Study:
- To evaluate the efficacy of Goserelin, a gonadotropin-releasing hormone (GnRH) analogue, in patients with advanced ovarian cancer.
- To assess Goserelin's potential as a therapeutic alternative when cytotoxic treatments fail.
Main Methods:
- A study involving 23 ovarian cancer patients with progressive disease receiving second- or third-line polychemotherapy.
- Subcutaneous administration of 3.6 mg Goserelin monthly until tumor progression.
- Analysis of response rates and time to tumor progression.
Main Results:
- Partial response was observed in 17.4% of patients, and stable disease in 30.4%.
- Median time to tumor progression varied significantly by response group (8.5 months for partial response, 5.3 for stable disease, 2.1 for progression).
- Positive responses were more common in patients with grade 2 or grade 3 tumors.
Conclusions:
- Goserelin exhibits antitumor activity in advanced ovarian carcinoma, including grade 2 and grade 3 tumors.
- Goserelin represents a viable therapeutic option for ovarian cancer patients who have exhausted cytotoxic treatment regimens.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
01:24Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...